

Target	
Mechanism of Action	<ul style="list-style-type: none"> <li>Inhibition of ROS1/MAPK/Akt signal pathway</li> </ul>
Indication - Primary	<ul style="list-style-type: none"> <li>Non-small-cell lung cancer (NSCLC)</li> </ul>
Indication - Expansion	<ul style="list-style-type: none"> <li>Brain tumor</li> <li>Biliary tract cancer</li> <li>Diffusive gastric cancer</li> </ul>
Route of Administration	<ul style="list-style-type: none"> <li>PO (QD)</li> </ul>
Competitive Advantage	<ul style="list-style-type: none"> <li>Highly potent against G2032R mutant</li> <li>Good PK and BBB properties</li> <li>Best-in-class</li> </ul>
Data Files	<ul style="list-style-type: none"> <li>Medicinal Chemistry Approach</li> <li>in vitro data: enzyme &amp; cell assay, CYPs, hERG, MS</li> <li>in vivo data (wt &amp; mt)</li> <li>ADME/PK</li> </ul>
IP Status	<ul style="list-style-type: none"> <li>In preparation</li> <li>owned by KRICT and NCC</li> </ul>
Collaboration Model	<ul style="list-style-type: none"> <li>Licensing out</li> <li>Collaborative research followed by licensing out</li> </ul>
Contact (Science)	<ul style="list-style-type: none"> <li>Chang-Soo Yun (csyun@krict.re.kr, +82-42-860-7315)</li> </ul>
Contact (Licensing)	<ul style="list-style-type: none"> <li>Moon Geun Jung (Technology marketing office, mgjung@krict.re.kr, +82-42-860-7746)</li> <li>Choon-gil Kim (Technology marketing office, joykim@krict.re.kr, +82-42-860-7079)</li> <li>Kyung Sun Choi (Technology marketing office, chanian@krict.re.kr, +82-42-860-7076)</li> </ul>